Translating Clinical Trials into Meaningful Outcomes 5951
Patricia M. LoRusso, Lowell E. Schnipper, David J. Stewart, Scott A. Boerner, Steven D. Averbuch and Walter Wolf

Making the Investigational Oncology Pipeline More Efficient and Effective: Are We Headed In the Right Direction? 5956
Patricia M. LoRusso, Aparna B. Anderson, Scott A. Boerner and Steven D. Averbuch

Evaluating Patient-Centered Outcomes in the Randomized Controlled Trial and Beyond: Informing the Future with Lessons from the Past 5963
Christopher M. Booth

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? 5972
Tito Fojo and David R. Parkinson

Explaining Marginal Benefits to Patients, When “Marginal” Means Additional but Not Necessarily Small 5981
Thomas J. Smith and Bruce E. Hillner

The 2010 Health Care Reform Act: A Potential Opportunity to Advance Cancer Research by Taking Cancer Personally 5987
William S. Dalton, Daniel M. Sullivan, Timothy J. Yeatman and David A. Fenstermacher

The Impact of Insurance on Access to Cancer Clinical Trials at a Comprehensive Cancer Center 5997
Justin F. Klamerus, Suanna S. Bruinooge, Xiaobu Ye, Mandi L. Klamrers, Dorothy Damron, Dina Lansey, John C. Lowery, Luis A. Diaz Jr., Jean G. Ford, Norma Kanarek and Charles M. Rudin

Value and Cancer Care: Toward an Equitable Future 6004
Lowell E. Schnipper, Neal J. Meropol and Dan W. Brock
**HUMAN CANCER BIOLOGY**

6009

**IQGAP1 Plays an Important Role in the Invasiveness of Thyroid Cancer**  
Zhi Liu, Dingxie Liu, Ermal Bojdani, Adel K. El-Naggar, Vasily Vasko and Mingzhao Xing

**IMAGING, DIAGNOSIS, PROGNOSIS**

6083

**Genotypic Profiling of 452 Choroidal Melanomas with Multiplex Ligation-Dependent Probe Amplification**  
Bertil Damato, Justyna A. Dopierala, Sarah E. Coupland

6093

**Prognostic Value of Baseline [18F] Fluorodeoxyglucose Positron Emission Tomography and 99mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer**  

**CANCER THERAPY: PRECLINICAL**

6019

**Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model**  
Ping Yu, Jason C. Steel, Meili Zhang, John C. Morris and Thomas A. Waldmann

6029

**Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma**  
Saadia A. Aziz, Lucia B. Jilaveanu, Christopher Zito, Robert L. Camp, David L. Rimm, Patricia Conrad and Harriet M. Kluger

6040

**The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations**  

6049

**Microenvironmental Regulation of Glioblastoma Radiosensitivity**  
Muhammad Jamal, Barbara H. Rath, Eli S. Williams, Kevin Camphausen and Philip J. Tofilon

6060

**The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance**  
Karisa C. Schreck, Pete Tayor, Luigi Marchionni, Vidyas Gopalakrishnan, Eli E. Bar, Nicholas Gaiano and Charles G. Eberhart

6071

**A Hypoxia- and o-Fetoprotein-Dependent Oncolytic Adenovirus Exhibits Specific Killing of Hepatocellular Carcinomas**  
Oh-Joon Kwon, Pyung-Hwan Kim, Steven Huyn, Lily Wu, Minjung Kim and Chae-Ok Yun

**CANCER THERAPY: CLINICAL**

6122

**CDS+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma**  
Mark E. Dudley, Colin A. Gross, Michelle M. Langhan, Marcos R. Garcia, Richard M. Sherry, James C. Yang, Giao Q. Phan, Udai S. Kammula, Marybeth S. Hughes, Deborah E. Citrin, Nicholas P. Restifo, John R. Wunderlich, Peter A. Prieto, Jenny J. Hong, Russell C. Langan, Daniel A. Zlott, Kathleen E. Morton, Donald E. White, Carolyn M. Laurencot and Steven A. Rosenberg

6132

**Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAh-009 in Patients with Mesothelin-Expressing Cancers**  
Raffit Hassan, Steven J. Cohen, Martin Phillips, Ira Pastan, Elad Sharon, Ronan J. Kelly, Charles Schweizer, Susan Weil and Daniel Laheru
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine


Tumor Survivin Is Downregulated by the Antisense Oligonucleotide LY2181308: A Proof-of-Concept, First-in-Human Dose Study

Denis C. Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies, Valérie André, Sunil Kadam, Michael Burgess, Christopher Slapak, Anna L. Olsen, Peter J. McHugh, Johann S. de Bono, Julian Matthews, Azeem Saleem and Patricia Price

chromosome 17 polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Letter

Cathy B. Moelans, Roel A. de Weger and Paul J. van Diest

LETTERS TO THE EDITOR

Chromosome 17 Polysomy without HER2 Amplification Does Not Predict Response to Lapatinib in Metastatic Breast Cancer—Response

Leona Downey and Robert Livingston

Do Rectal Cancer Patients with PIK3CA Mutations Benefit from Preoperative Radiotherapy with Regard to Local Recurrences?

Youji He, Laura J. Van’t Veer, Marta Lopez-Yurda, Cornelis J.H. van de Velde and Corrie A.M. Marijnen

Clinical Usefulness of Microarrays for Cancer Prognosis in 2010—Letter

Serge Koscielny and Stefan Michiels

Statistical Evaluation of Clinical Usefulness of Microarrays for Cancer Prognosis Needs to be Placed in the Context of Clinical Reality—Response

Weida Tong and Xiaohui Fan

Acknowledgment to Reviewers

The Journal of Clinical and Translational Research v www.aacrjournals.org

on December 31, 2017. © 2010 American Association for Cancer Research.
ABOUT THE COVER

Intracerebral xenograft initiated from the CD133+ glioblastoma stem-like cell line GBM1. At the initial signs of morbidity (94 days after implantation) a representative mouse was euthanized and the brain tumor prepared for histological analyses. This figure shows the immunofluorescent analyses of GFAP (red) and III tubulin (green) with nuclei counterstained with DAPI (blue) at 20x magnification. For details, see the article by Jamal and colleagues on page 6049 of this issue.
Clinical Cancer Research

16 (24)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/24

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/16/24.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.